> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Viatris Raises 2026 Profit Targets Despite A $325 Million Quarterly Loss
- URL: https://www.bullished.co/viatris-raises-2026-profit-targets-despite-a-325-million-quarterly-loss-bd327c98/
- Published: 2026-11-05T18:54:52.000Z
- Updated: 2026-11-05T18:54:52.000Z
- Description: A $453.2 million tax provision drove the third-quarter loss on flat sales, while the drugmaker lifted its adjusted EPS midpoint to $2.60.
- Author: Matteo Parrino
- Tags: Earnings, VTRS, Industry: Healthcare

[Viatris](https://www.bullished.co/tag/vtrs/), a global healthcare company that sells generics, brand-name drugs and innovative medicines, reported a [U.S. GAAP net loss of $325 million](https://www.sec.gov/Archives/edgar/data/0001792044/000179204426000053/exhibit991-3q26earningsrel.htm?ref=bullished.co) for the third quarter on essentially flat revenue of $3.75 billion. It still raised the midpoints of its 2026 guidance ranges on every key metric, in results released Thursday.

## A tax bill behind the loss

The company said the loss was primarily driven by a higher income tax provision, tied to losses in jurisdictions where minimal benefit can be realized. The provision came to $453.2 million, against $120.3 million a year earlier. The loss compares with $128 million in the third quarter of 2025, or $0.28 a share against $0.11.

Operations looked steadier. Adjusted EBITDA, a measure that strips out items such as restructuring and acquisition costs, was [$1.20 billion](https://www.prnewswire.com/news-releases/viatris-reports-third-quarter-2026-financial-results-302929937.html?ref=bullished.co), up 4% as reported and 1% on an operational basis. Adjusted EPS was $0.71, up 6%. Free cash flow, excluding transaction and restructuring costs, was $895 million.

Total revenues were [$3,749.5 million](https://www.prnewswire.com/news-releases/viatris-reports-third-quarter-2026-financial-results-302929937.html?ref=bullished.co), against $3,759.9 million a year earlier. Greater China net sales rose 14% to $702.6 million, while Emerging Markets fell 7% and Developed Markets slipped 2%.

## Higher midpoints, a Nashik drag

The new guidance midpoints, set against those given on August 6:

- Adjusted EPS: $2.60, from $2.52.
- Adjusted EBITDA: $4.5 billion, from $4.4 billion.
- Total revenue: $14.8 billion, from $14.75 billion.
- Free cash flow excluding transaction and restructuring costs: $2.3 billion, from $2.2 billion.

Supply constraints are a drag. In September the FDA told Viatris its oral solid dose plant in Nashik, India was classified Official Action Indicated, after observations in May. The company voluntarily suspended manufacturing there in October and expects to resume production in the first quarter of 2027.

Viatris put the total revenue hit from supply constraints at about $100 million in the third quarter and expects roughly $100 million more in the fourth. It cited constraints in Europe and Emerging Markets as well.

## Pacira deal and buybacks

Viatris agreed in October to buy Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, and expects to close by the end of November. The new guidance excludes any contribution from Pacira. Interim CFO Paul Campbell said the deal should have minimal impact on gross leverage.

Through September 30, the company returned about $717 million to shareholders, roughly $300 million of it through buybacks. About $700 million remains under the repurchase authorization. Viatris shares were at $19.01, down about 1% in Thursday trading.

CEO Scott A. Smith also pointed to the potential upcoming approval and launch of fast-acting meloxicam, and to FDA approval of RYZUMVI for presbyopia.

The Pacira closing targeted for the end of November is the next marker, with Nashik production not due back until the first quarter of 2027.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Viatris Inc (VTRS)](https://www.sec.gov/Archives/edgar/data/0001792044/000179204426000053/vtrs-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exhibit991-3q26earningsrel.htm — Viatris Inc 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001792044/000179204426000053/exhibit991-3q26earningsrel.htm?ref=bullished.co) — SEC EDGAR
- [Viatris Reports Third-Quarter 2026 Financial Results](https://www.prnewswire.com/news-releases/viatris-reports-third-quarter-2026-financial-results-302929937.html?ref=bullished.co) — prnewswire.com

### More on Viatris

- [Viatris CEO Won't Guide 2027 But Calls Analyst's EBITDA Math 'In The Ballpark'](https://www.bullished.co/viatris-ceo-wont-guide-2027-but-calls-analysts-ebitda-math-in-the-ballpark-64d2777d/)
- [Viatris Agrees To Buy Pacira For $36.50 A Share, A $1.65 Billion Bet On Non-Opioid Pain Drugs](https://www.bullished.co/viatris-agrees-to-buy-pacira-for-36-50-a-share-a-1-65-billion-bet-on-non-opioid-pain-drugs-d939be3e/)

[All Viatris (VTRS) coverage →](https://www.bullished.co/tag/vtrs/)